Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02865408
NA

Amino Acid Nutrition in the Critically-ill

Sponsor: Arnold Kristof

View on ClinicalTrials.gov

Summary

Enhancing the anabolic effect of nutrition in critically ill patients by administering exogenous amino acids.

Official title: Enhancing the Anabolic Effect of Nutrition in Critically Ill Patients by Administering Exogenous Amino Acids

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2017-03-01

Completion Date

2026-02-28

Last Updated

2025-10-06

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Peptamen 1.5% via enteral

Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

DIETARY_SUPPLEMENT

Prosol 20% IV to 1.75g/kg/day

Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.

DIETARY_SUPPLEMENT

Prosol 20% IV to 2.5g/kg/day

Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.

Locations (1)

McGill University health Centre

Montreal, Quebec, Canada